Pfizer spinout woos Otsuka vet Raymond Sanchez to lead CNS pipeline work; Joe Anderson returns to Arix helm
→ Four months after plopping itself down in the center of the neurosciences field with a pipeline from Pfizer and $350 million in launch cash from Bain Capital, Cerevel Therapeutics has recruited a seasoned central nervous system drug developer to become its CMO. Raymond Sanchez, who jumps from Otsuka, is tasked with shepherding Cerevel’s Parkinson’s (dopamine D1 agonist) and epilepsy (GABA A positive modulator) programs into Phase III. At the Japanese pharma, Sanchez oversaw CNS work at Avanir among other responsibilities.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.